

Reference:	FOI.5422.21
Subject:	Prescribed products
Date of Request:	23 February 2021

Requested:

Please can you send me the following information:

In the last 6 months, how many patients have been prescribed each of these products?

- Amgevita (adalimumab)
- Imraldi (adalimumab)
- Hyrimoz (adalimumab)
- Cimzia (certolizumab pegol)
- Rinvoq (upadacitinib)
- Tremfya (guselkumab)
- Skyrizi (risankizumab)
- Kyntheum (brodalumab)
- Taltz (ixekizumab)

Response:

Hywel Dda University health Board (UHB) provides, within the table below, the number of patients prescribed the listed medications, during the period, 1 August 2020 to 31 January 2021.

Medication	Number of patients
Amgevita (adalimumab)	162
Imraldi (adalimumab)	154
Hyrimoz (adalimumab)	0
Cimzia (certolizumab pegol)	49
Rinvoq (upadacitinib)	0
Tremfya (guselkumab)	0
Skyrizi (risankizumab)	0
Kyntheum (brodalumab)	0
Taltz (ixekizumab)	*

Where the figures in the table has been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the Data Protection Act 2018/ General Data Protection Regulations 2016 (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 defines personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.